- Home
- AGMH vs THAR Comparison
AGMH vs THAR Comparison
Compare AGMH & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- THAR
- Stock Information
- Founded
- AGMH 2015
- THAR 2017
- Country
- AGMH Hong Kong
- THAR United States
- Employees
- AGMH N/A
- THAR N/A
- Industry
- AGMH EDP Services
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- THAR Health Care
- Exchange
- AGMH Nasdaq
- THAR Nasdaq
- Market Cap
- AGMH 3.5M
- THAR 3.3M
- IPO Year
- AGMH 2018
- THAR 2022
- Fundamental
- Price
- AGMH $3.11
- THAR $1.51
- Analyst Decision
- AGMH
- THAR Strong Buy
- Analyst Count
- AGMH 0
- THAR 1
- Target Price
- AGMH N/A
- THAR $17.00
- AVG Volume (30 Days)
- AGMH 857.7K
- THAR 26.3K
- Earning Date
- AGMH 06-18-2025
- THAR 05-12-2025
- Dividend Yield
- AGMH N/A
- THAR N/A
- EPS Growth
- AGMH N/A
- THAR N/A
- EPS
- AGMH 6.43
- THAR N/A
- Revenue
- AGMH $32,044,575.00
- THAR N/A
- Revenue This Year
- AGMH N/A
- THAR N/A
- Revenue Next Year
- AGMH N/A
- THAR N/A
- P/E Ratio
- AGMH $0.44
- THAR N/A
- Revenue Growth
- AGMH N/A
- THAR N/A
- 52 Week Low
- AGMH $1.09
- THAR $0.95
- 52 Week High
- AGMH $109.50
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- AGMH 44.31
- THAR 54.61
- Support Level
- AGMH $2.11
- THAR $1.41
- Resistance Level
- AGMH $4.93
- THAR $1.64
- Average True Range (ATR)
- AGMH 0.67
- THAR 0.11
- MACD
- AGMH 0.00
- THAR 0.01
- Stochastic Oscillator
- AGMH 35.46
- THAR 63.86
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.